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INTRODUCTION
Bartonella henselae is an intraerythrocytic pathogen
of cats, transmitted by ﬂeas. A remarkable feature
of the genus Bartonella is the ability of a single
species to cause either acute or chronic infection
or either vascular proliferative or suppurative
manifestations [1,2]. B. henselae has been associ-
ated with an increasing spectrum of clinical
situations, including endocarditis, bacillary angi-
omatosis, peliosis hepatitis and cat scratch disease
(CSD). Some of the diseases due to Bartonella
species can resolve spontaneously without treat-
ment, but in other cases, the disease is fatal
without antibiotic treatment and ⁄ or surgery [2].
The clinical situations are so different that a single
treatment for all Bartonella-related diseases has
not been identiﬁed, and the approach to treatment
must be adapted to each species and clinical
situation [2].
The objective of this study was to select
resistant mutants of gentamicin, amoxicillin and
doxycycline in vitro and to understand the mech-
anism of resistance at the molecular level.
MATERIALS AND METHODS
The B. henselae strain Marseille was grown on Columbia 5%
sheep blood agar plates. The plates were placed in polyeth-
ylene bags and incubated at 37C in a 5% CO2 -enriched
atmosphere (Genbag CO2 system). Selection of antibiotic-
resistant mutants was performed by serial passages of
B. henselae in blood agar plates containing a disk of antibiotic
(gentamicin, amoxicillin and doxycycline) (Mast Diagnostics,
Amiens, France), initially placed in the corner or in the centre
of the plate according to the measurement of diameter of
growth inhibition as previously described [3,4]. The plates
were incubated at 37C and diameters of growth inhibition (in
mm) were measured every 2 weeks. The conﬂuent growth
outside the zone of inhibition was harvested with an inocu-
lation loop and subcultured every 2 weeks until the strain
became completely resistant. The B. henselae mutant strain
obtained was screened for the presence of mutations in the 16S
rDNA gene by PCR ampliﬁcation and DNA sequencing using
speciﬁc oligonucleotidic primers targeting the 16S rDNA gene.
Primers used were Bh16SF1 (TTCAATATGAGAGTTTGA),
Bh16SR1 (ACGGCTAACATTCATCGT) and Bh16SF2 (GA-
ATTCCGAGTGTAGAGG), Bh16SR2 (AGAAAGGAGGT-
GATCCAG). The obtained nucleotide sequences of candidate
genes were compared using the CLUSTAL W program
(http://www.ebi.ac.uk/Tools/clustalw2/index.htm) to look
at possible mutations known to be associated with antibiotic
resistance.
RESULTS
No resistant mutant of B. henselae was obtained
with either amoxicillin or doxycycline even after
16 (32 weeks) and 24 passages (48 weeks), respec-
tively. Conversely, a gentamicin-resistant strain
of B. henselae was obtained in vitro after a long
period of study (9 passages, 18 weeks; diameter of
inhibition fell from 51 mm to <6 mm). The 16S
rRNA gene, the candidate gene for gentamicin
resistance, was characterised by sequence analy-
sis. The gentamicin-resistant mutant of B. henselae
harboured an A1408G mutation in the 16S rRNA
gene, as depicted with a double peak A ⁄G
(Fig. 1a,b).
DISCUSSION
In the present study, we have described the
molecular characterisation of a mutant strain
obtained in vitro conferring resistance to gentami-
cin for B. henselae. Aminoglycoside antibiotics
target the 16S ribosomal RNA bacterial A site and
induce misreading of the genetic code (Fig. 1c).
Aminoglycosides kill bacteria by inhibiting protein
synthesis via binding to the 16S rRNA and dis-
rupting the integrity of the bacterial cell membrane
[5]. The most common mechanism of resistance to
aminoglycosides is their structuralmodiﬁcation by
speciﬁc enzymes produced by resistant organisms
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[5]. Other mechanisms of resistance include alter-
ation of the 30S ribosomal subunit target by
mutation in the 16S rRNA gene, methylation of
the aminoglycoside-binding site, and reduction of
the intracellular concentration of aminoglycosides
by changes in outer membrane permeability,
decreased inner membrane transport and active
efﬂux [5]. In the present study, our B. henselae
mutant strain showed an A1408G mutation in the
16S rRNA gene as a double peak. Because the
genome of B. henselae contains two copies of 16S
rRNA genes, this means that a change in one of the
two copies of the 16S rRNAgene could be sufﬁcient
to confer gentamicin resistance, as recently dem-
onstrated for erythromycin resistance and the 23S
RNA gene in B. henselae [3]. Among all the A-site
mutations that confer aminoglycoside resistance,
spontaneous and recombinant mutants containing
the A1408G mutation display the highest levels of
resistance. This mutation is the most frequently
found in clinical isolates as well. Although we
obtained a gentamicin-resistant mutant in vitro,
this mutant was obtained only after nine subcul-
tures (18 weeks), suggesting that selection of such
gentamicin-resistant strains is not likely to occur in
vivo because this antibiotic is used for the treatment
of Bartonella-related infections for a duration of
therapy of 2 weeks in combination with either
doxycycline or amoxicillin. Because we were not
able to select any B. henselae strain resistant to
doxycycline or amoxicillin even after 1 year of
subculture, our in-vitro study supports the effec-
tiveness of the current antibiotic regimen (combi-
nation of gentamicin with doxycycline or
amoxicillin) for the treatment of B. henselae infec-
tions, especially for endocarditis.
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Fig. 1. Sequence result of gentamicin-susceptible (a) and
gentamicin-resistant (b) strains of B. henselaeMarseille with
16S primers showing A to G mutation at position 1408 of
the 16S rRNA gene (E. coli numbering) and bacterial 30S
ribosomal RNA subunit with 16S rRNA, target site for
gentamicin (c).
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